ArticleEuropean journal of nuclear medicine and molecular imaging2020
CTumorGAN: a unified framework for automatic computed tomography tumor segmentation.
Article in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Semantic Segmentation of CT Liver Structures: A Systematic Review of Recent Trends and Bibliometric Analysis : Neural Network-based Methods for Liver Semantic Segmentation.Journal of medical systems · 2024Pooled it
- Selection of proper artificial intelligence techniques developed for CT scan image analysis of liver cancer using fuzzy AHP-TOPSIS.BMC medical imaging · 2026Article
- 3D Adversarial Segmentation of Kidney-Transplant Across Multiple MRI Sequences Using Probabilistic and Anatomical Priors.Diagnostics (Basel, Switzerland) · 2026Article
- Development and validation of a deep learning-based framework for automated lung CT segmentation and acute respiratory distress syndrome prediction: a multicenter cohort study.EClinicalMedicine · 2024Article
- Imaging-based deep learning in kidney diseases: recent progress and future prospects.Insights into imaging · 2024Review
- Experimental Examination of Conventional, Semi-Automatic, and Automatic Volumetry Tools for Segmentation of Pulmonary Nodules in a Phantom Study.Diagnostics (Basel, Switzerland) · 2023Article
- Deep Learning-Based Delayed PET Image Synthesis from Corresponding Early Scanned PET for Dosimetry Uptake Estimation.Diagnostics (Basel, Switzerland) · 2023Article
- A Novel Generative Adversarial Network-Based Approach for Automated Brain Tumour Segmentation.Medicina (Kaunas, Lithuania) · 2023Article
- Research on Segmentation Technology in Lung Cancer Radiotherapy Based on Deep Learning.Current medical imaging · 2023Review
- Kidney Tumor Semantic Segmentation Using Deep Learning: A Survey of State-of-the-Art.Journal of imaging · 2022Article
- Generative adversarial networks and its applications in the biomedical image segmentation: a comprehensive survey.International journal of multimedia information retrieval · 2022Review
- Accurate segmentation for different types of lung nodules on CT images using improved U-Net convolutional network.Medicine · 2021Article
- Automatic segmentation of lung tumors on CT images based on a 2D & 3D hybrid convolutional neural network.The British journal of radiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeUnlike the normal organ segmentation task, automatic tumor segmentation is a more challenging task because of the existence of similar visual characteristics between tumors and their surroundings, especially on computed tomography (CT) images with severe low contrast resolution, as well as the diversity and individual characteristics of data acquisition procedures and devices. Consequently, most of the recently proposed methods have become increasingly difficult to be applied on a different tumor dataset with good results, and moreover, some tumor segmentors usually fail to generalize beyond those datasets and modalities used in their original evaluation experiments.
methodsIn order to alleviate some of the problems with the recently proposed methods, we propose a novel unified and end-to-end adversarial learning framework for automatic segmentation of any kinds of tumors from CT scans, called CTumorGAN, consisting of a Generator network and a Discriminator network. Specifically, the Generator attempts to generate segmentation results that are close to their corresponding golden standards, while the Discriminator aims to distinguish between generated samples and real tumor ground truths. More importantly, we deliberately design different modules to take into account the well-known obstacles, e.g., severe class imbalance, small tumor localization, and the label noise problem with poor expert annotation quality, and then use these modules to guide the CTumorGAN training process by utilizing multi-level supervision more effectively.
resultsWe conduct a comprehensive evaluation on diverse loss functions for tumor segmentation and find that mean square error is more suitable for the CT tumor segmentation task. Furthermore, extensive experiments with multiple evaluation criteria on three well-established datasets, including lung tumor, kidney tumor, and liver tumor databases, also demonstrate that our CTumorGAN achieves stable and competitive performance compared with the state-of-the-art approaches for CT tumor segmentation.
conclusionIn order to overcome those key challenges arising from CT datasets and solve some of the main problems existing in the current deep learning-based methods, we propose a novel unified CTumorGAN framework, which can be effectively generalized to address any kinds of tumor datasets with superior performance.
Indexed as
Identifiers
32222809What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.